Cybin Inc. (OTCMKTS:CLXPF) has received an average recommendation of “Buy” from the six ratings firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $10.50.
Several equities research analysts recently issued reports on CLXPF shares. Zacks Investment Research cut Cybin from a “buy” rating to a “hold” rating in a report on Tuesday, August 3rd. Stifel Nicolaus boosted their target price on Cybin from C$11.00 to C$15.00 and gave the stock a “buy” rating in a report on Monday, June 21st. They noted that the move was a valuation call. Aegis began coverage on Cybin in a report on Thursday, July 8th. They set a “buy” rating and a $9.00 target price on the stock. Finally, HC Wainwright began coverage on Cybin in a report on Monday, July 26th. They set a “buy” rating and a $8.00 target price on the stock.
CLXPF stock traded down $0.05 during trading on Friday, hitting $2.03. The stock had a trading volume of 1,098,097 shares, compared to its average volume of 551,962. Cybin has a twelve month low of $0.49 and a twelve month high of $3.38. The stock has a market capitalization of $301.65 million and a P/E ratio of -8.46. The company’s 50-day moving average price is $2.29 and its two-hundred day moving average price is $2.00.
Cybin Inc, a life sciences company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Natures Journey. The Serenity Life segment engages in the research and development of pharmaceutical and nutraceutical psilocybin products.
Read More: How is inflation measured?
Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.